---
schema_version: "secwatch.filing_event.v1"
accession: "0001919246-26-000014"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:42:34.139412+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pelthos Q4 ZELSUVMI sales $9.1M, up 28% QoQ; adds XEPI and XEGLYZE

## Summary
- ZELSUVMI net product revenue $9.1M in Q4 2025 vs $7.1M in Q3; full-year 2025 total revenue $16.8M.
- 8,948 units dispensed, 2,712 unique prescribers; Q4 units up 129% QoQ to 6,232.
- Acquired XEPI (impetigo) Nov 2025 and XEGLYZE (head lice) Jan 2026; sales force expanded to 64.
- Closed $18M convertible notes Nov 2025 and $50M term loan ($30M drawn) Jan 2026; cash $18M at year-end.
- Operating loss improved to $12M in Q4 from $15.4M in Q3; adjusted EBITDA loss improved 22% QoQ.

## SEC filing metadata
- accession: 0001919246-26-000014
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/0001919246-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/pths-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001919246-26-000014
- JSON: https://secwatch.observer/filing/0001919246-26-000014.json
- Plain text: https://secwatch.observer/filing/0001919246-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.